FDA gives Lannett more time to make its case for ADHD drug

The Food and Drug Administration has decided to give Lannett Co. Inc. more time to show why its generic ADHD drug should be allowed to remain in the market. Back in October, the FDA informed the Northeast Philadelphia generic drug manufacturer that the agency was preparing to withdraw its approval of the company’s Methylphenidate Hydrochloride extended-release tablets, prescribed to treat attention deficit hyperactivity disorder, based in part on re ports by patients that the therapeutics benefits…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news